Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of €4 million to Evotec. The milestone was for the transition of a respiratory program into preclinical development.
Dr. Mario Polywka, Chief Operating Officer of Evotec commented: “This is the sixteenth milestone achieved as part of our alliance with Boehringer Ingelheim and represents an important transition of this program into preclinical development. The alliance continues to achieve significant scientific and commercial success, reflecting the truly collaborative efforts of teams from Evotec and Boehringer Ingelheim.”
Date: June 5, 2012
Source: Evotec AG
Filed Under: Drug Discovery